Oral Icariin Nanoparticles Ameliorate Nonalcoholic Fatty Liver Disease by Alleviating Oxidative Stress
Source abstract
Abstract
High Resolution Image Download MS PowerPoint Slide Chronic inflammatory liver conditions, such as nonalcoholic fatty liver disease (NAFLD), are frequently exacerbated by oxidative stress, rendering the neutralization of reactive oxygen species (ROS) crucial for their amelioration. Oral administration of nanoparticles (NPs) presents an optimal strategy for NAFLD management due to its convenience. This research aimed to overcome the poor water solubility and low bioavailability of icariin (ICA) by engineering an oral nanosystem, ICA-loaded poly(lactic- co -glycolic acid)-poly(ethylene glycol) (PLGA) NPs with chitosan (CS) and mannose surface modification (ICA-NPs), to augment ICA’s antioxidant potency against NAFLD. Methods involved comprehensive in vitro characterization of ICA-NPs (including dispersibility, biocompatibility, HepG2 targeting, and ROS scavenging capabilities) and in vivo studies in high-fat diet (HFD)-induced NAFLD mice, assessing liver accumulation, ROS scavenging, and antiobesity effects across multiple experimental groups. Results demonstrated that this targeted oral NP system significantly amplified ICA’s therapeutic impact, leading to substantial reductions in body weight, diminished white adipose tissue accumulation, decreased hepatic lipid content, improved hepatic function, and a notable suppression of ROS in the livers of NAFLD-afflicted mice. In conclusion, by harnessing the precision of targeted delivery, this oral nanosystem not only enhances ICA’s therapeutic efficacy but also establishes a safe and effective platform for the oral administration of herbal remedies for liver conditions, suggesting a promising avenue for advancing herbal medicine in liver disease treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Medicinal Plant Pharmacodynamics Research · Liver Disease Diagnosis and Treatment · Osteoarthritis Treatment and Mechanisms
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
The Affiliated Dongguan Songshan Lake Central Hospital
Guangdong Medical University
Key Laboratory of Human Microbiome and Chronic Diseases (Sun Yat-sen University)
Ministry of Education
Guangdong Institute of Gastroenterology, The Sixth Affiliated Hospital
Sun Yat-sen University
Changji Vocational and Technical College
School of Pharmacy
Funding
Special Project for Clinical and Basic Sci&Tech Innovation of Guangdong Medical University
References (46)
Show source-provided references
1. 10.1186/s12902-022-00980-110.1186/s12902-022-00980-1 ↗
2. 10.7759/cureus.5015910.7759/cureus.50159 ↗
3. 10.1111/joim.1353110.1111/joim.13531 ↗
4. 10.3390/antiox1002017410.3390/antiox10020174 ↗
5. 10.3389/fmed.2021.59537110.3389/fmed.2021.595371 ↗
6. 10.3390/jfb1401004410.3390/jfb14010044 ↗
7. 10.1016/bs.apha.2019.10.00410.1016/bs.apha.2019.10.004 ↗
8. 10.3390/ijms2314751910.3390/ijms23147519 ↗
9. Development and Evaluation of Icariin-Loaded PLGA-PEG Nanoparticles for Potentiation the Proapoptotic Activity in Pancreatic Cancer Cells - PubMed. . https://pubmed.ncbi.nlm.nih.gov/34668089/ (accessed 2025-10-29).
10. 10.1155/2021/404141510.1155/2021/4041415 ↗
11. 10.1007/s12274-017-1918-310.1007/s12274-017-1918-3 ↗
12. 10.3390/polym1313220810.3390/polym13132208 ↗
13. 10.3390/ijms2503137010.3390/ijms25031370 ↗
14. 10.3390/pharmaceutics1206059010.3390/pharmaceutics12060590 ↗
15. 10.1002/hep.2070110.1002/hep.20701 ↗
16. 10.1016/j.ijbiomac.2022.01.19410.1016/j.ijbiomac.2022.01.194 ↗
17. 10.1016/j.ejphar.2018.10.00610.1016/j.ejphar.2018.10.006 ↗
18. 10.1080/21655979.2021.195555010.1080/21655979.2021.1955550 ↗
19. FTIR image showing PLGA – PEG – CD14 encapsulation of miltefosine. | Download Scientific Diagram . https://www.researchgate.net/figure/FTIR-image-showing-PLGA-PEG-CD14-encapsulation-of-miltefosine_fig 1_283356783 (accessed 2025-10-29).
20. 10.1016/j.jconrel.2014.03.02610.1016/j.jconrel.2014.03.026 ↗
21. Infrared spectroscopy of flavones and flavonols. Reexamination of the hydroxyl and carbonyl vibrations in relation to the interactions of flavonoids with membrane lipids - ScienceDirect . https://www.sciencedirect.com/science/article/abs/pii/S1386142517309678 (accessed 2025-10-29).
22. D’Souza, S. A Review of In Vitro Drug Release Test Methods for Nano-Sized Dosage Forms Advances in Pharmaceutics 2014 10.1155/2014/30475710.1155/2014/304757 ↗
23. 10.3390/ijms24151251010.3390/ijms241512510 ↗
24. 10.1039/D3BM00802A10.1039/D3BM00802A ↗
25. Icariin Alleviates Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome by Improving Liver Fatty Acid Oxidation and Inhibiting Lipid Accumulation . https://www.mdpi.com/1420-3049/28/2/517 (accessed 2025-11-20).10.3390/molecules28020517 ↗
26. 10.1016/j.jconrel.2025.11368010.1016/j.jconrel.2025.113680 ↗
27. 10.1002/mba2.6510.1002/mba2.65 ↗
28. Thirty years of NRF2: advances and therapeutic challenges - PubMed . https://pubmed.ncbi.nlm.nih.gov/40038406/ (accessed 2025-11-20).
29. 10.3390/biomedicines1202040310.3390/biomedicines12020403 ↗
30. 10.1134/S000629792111005510.1134/S0006297921110055 ↗
31. 10.1016/j.phytochem.2023.11384110.1016/j.phytochem.2023.113841 ↗
32. 10.3390/molecules2802051710.3390/molecules28020517 ↗
33. 10.1186/s40779-022-00433-910.1186/s40779-022-00433-9 ↗
34. Orally Deliverable Sequence-Targeted Fucoxanthin-Loaded Biomimetic Extracellular Vesicles for Alleviation of Nonalcoholic Fatty Liver Disease | ACS Applied Materials & Interfaces . https://pubs.acs.org/doi/10.1021/acsami.3c18029 (accessed 2025-10-29).
35. 10.1021/acsnano.8b0431510.1021/acsnano.8b04315 ↗
36. 10.1016/j.jconrel.2016.06.01610.1016/j.jconrel.2016.06.016 ↗
37. 10.1002/adma.20180774810.1002/adma.201807748 ↗
38. Quantitative Structure–Activity Relationship Enables the Rational Design of Lipid Droplet-Targeting Carbon Dots for Visualizing Bisphenol A-Induced Nonalcoholic Fatty Liver Disease-like Changes | ACS Applied Materials & Interfaces . https://pubs.acs.org/doi/10.1021/acsami.1c13157 (accessed 2025-10-29).
39. 10.1021/acsami.4c0824010.1021/acsami.4c08240 ↗
40. 10.1016/j.matdes.2020.10880510.1016/j.matdes.2020.108805 ↗
41. 10.1021/acsami.1c1467410.1021/acsami.1c14674 ↗
42. 10.3390/antiox1307079710.3390/antiox13070797 ↗
43. 10.1016/j.freeradbiomed.2020.02.02510.1016/j.freeradbiomed.2020.02.025 ↗
44. 10.3390/antiox1307079710.3390/antiox13070797 ↗
45. 10.1016/B978-0-12-804274-8.00028-X10.1016/B978-0-12-804274-8.00028-X ↗
46. 10.1016/j.phymed.2025.15647210.1016/j.phymed.2025.156472 ↗